{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T18:25:11Z","timestamp":1781375111457,"version":"3.54.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T00:00:00Z","timestamp":1757289600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["2018-00706\/ESR-16-12287"],"award-info":[{"award-number":["2018-00706\/ESR-16-12287"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013226","name":"Les Laboratories Pierre Fabre","doi-asserted-by":"publisher","award":["2018-00603"],"award-info":[{"award-number":["2018-00603"]}],"id":[{"id":"10.13039\/100013226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014630","name":"Minist\u00e8re des Solidarit\u00e9s et de la Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014630","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014088","name":"AstraZeneca SAS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014088","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004099","name":"National League Against Cancer","doi-asserted-by":"publisher","award":["PHRC-K_2016-078"],"award-info":[{"award-number":["PHRC-K_2016-078"]}],"id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.esmoop.2025.105840","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T01:53:55Z","timestamp":1762394035000},"page":"105840","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["MOVIE phase II trial of tremelimumab plus durvalumab combined with metronomic oral vinorelbine in patients with head and neck cancer"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5393-5657","authenticated-orcid":false,"given":"E.","family":"Borcoman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Hervieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Cropet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Coquan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Guigay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6957-0894","authenticated-orcid":false,"given":"F.","family":"Rolland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7185-0809","authenticated-orcid":false,"given":"M.","family":"Bernadach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Charafe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Legrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Dass\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9772-4686","authenticated-orcid":false,"given":"C.","family":"Le Tourneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7570-7439","authenticated-orcid":false,"given":"A.","family":"Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.esmoop.2025.105840_bib1","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.3390\/cancers13081890","article-title":"Potential therapeutic significance of laminin in head and neck squamous carcinomas","volume":"13","author":"Meireles Da Costa","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105840_bib2","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105840_bib3","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41572-020-00224-3","article-title":"Head and neck squamous cell carcinoma","volume":"6","author":"Johnson","year":"2020","journal-title":"Nat Rev Dis Primers"},{"issue":"15","key":"10.1016\/j.esmoop.2025.105840_bib4","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1016\/j.ejca.2015.07.043","article-title":"Prognoses and improvement for head and neck cancers diagnosed in Europe in early 2000s: the EUROCARE-5 population-based study","volume":"51","author":"Gatta","year":"2015","journal-title":"Eur J Cancer"},{"issue":"9","key":"10.1016\/j.esmoop.2025.105840_bib5","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1634\/theoncologist.2009-0289","article-title":"Changes in survival in head and neck cancers in the late 20th and early 21st century: a period analysis","volume":"15","author":"Pulte","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.esmoop.2025.105840_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2020.105042","article-title":"Reprint of \u201cSquamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up\u201d","volume":"113","author":"Machiels","year":"2021","journal-title":"Oral Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105840_bib7","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.annonc.2020.07.011","article-title":"Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Machiels","year":"2020","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105840_bib8","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S1470-2045(16)30366-7","article-title":"Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial","volume":"17","author":"Hodi","year":"2016","journal-title":"Lancet Oncol"},{"issue":"14","key":"10.1016\/j.esmoop.2025.105840_bib9","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105840_bib10","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2217\/imt.13.9","article-title":"Tremelimumab: a review of development to date in solid tumors","volume":"5","author":"Tarhini","year":"2013","journal-title":"Immunotherapy"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105840_bib11","doi-asserted-by":"crossref","first-page":"7348","DOI":"10.1038\/s41467-021-26472-9","article-title":"Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma","volume":"12","author":"Vos","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.esmoop.2025.105840_bib12","doi-asserted-by":"crossref","first-page":"S1310","DOI":"10.1016\/j.annonc.2021.08.2113","article-title":"LBA36 Nivolumab (N) + ipilimumab (I) vs EXTREME as first-line (1L) treatment (tx) for recurrent\/metastatic squamous cell carcinoma of the head and neck (R\/M SCCHN): final results of CheckMate 651","volume":"32","author":"Argiris","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2025.105840_bib13","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.canlet.2017.01.040","article-title":"Metronomic chemotherapy and immunotherapy in cancer treatment","volume":"400","author":"Chen","year":"2017","journal-title":"Cancer Lett"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105840_bib14","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1186\/s12885-021-08373-8","article-title":"Induction chemotherapy combined with immunotherapy in locally advanced head and neck squamous cell carcinoma","volume":"21","author":"Li","year":"2021","journal-title":"BMC Cancer"},{"issue":"9","key":"10.1016\/j.esmoop.2025.105840_bib15","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","article-title":"Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study","volume":"18","author":"Overman","year":"2017","journal-title":"Lancet Oncol"},{"issue":"15","key":"10.1016\/j.esmoop.2025.105840_bib16","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1158\/1078-0432.CCR-22-0666","article-title":"Neoadjuvant chemoimmunotherapy for the treatment of locally advanced head and neck squamous cell carcinoma: a single-arm phase 2 clinical trial","volume":"28","author":"Zhang","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105840_bib17","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nrc1369","article-title":"The anti-angiogenic basis of metronomic chemotherapy","volume":"4","author":"Kerbel","year":"2004","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105840_bib18","doi-asserted-by":"crossref","first-page":"R15","DOI":"10.1172\/JCI8829","article-title":"Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity","volume":"105","author":"Klement","year":"2000","journal-title":"J Clin Invest"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105840_bib19","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1159\/000526481","article-title":"Current research status of metronomic chemotherapy in combination treatment of breast cancer","volume":"45","author":"Liu","year":"2022","journal-title":"Oncol Res Treat"},{"issue":"7","key":"10.1016\/j.esmoop.2025.105840_bib20","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nrclinonc.2014.89","article-title":"Metronomics: towards personalized chemotherapy?","volume":"11","author":"Andre","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105840_bib21","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1158\/1535-7163.MCT-13-0791","article-title":"Targeting microtubules by natural agents for cancer therapy","volume":"13","author":"Mukhtar","year":"2014","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105840_bib22","doi-asserted-by":"crossref","first-page":"566","DOI":"10.2174\/156800907781662266","article-title":"Targeting microtubules to inhibit angiogenesis and disrupt tumour vasculature: implications for cancer treatment","volume":"7","author":"Pasquier","year":"2007","journal-title":"Curr Cancer Drug Targets"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105840_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100646","article-title":"MOVIE: a phase I, open-label, multicenter study to evaluate the safety and tolerability of metronomic vinorelbine combined with durvalumab plus tremelimumab in patients with advanced solid tumors","volume":"7","author":"Vicier","year":"2022","journal-title":"ESMO Open"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105840_bib24","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.annonc.2022.12.008","article-title":"Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study","volume":"34","author":"Psyrri","year":"2023","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2025.105840_bib25","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.annonc.2020.04.001","article-title":"Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study","volume":"31","author":"Ferris","year":"2020","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105840_bib26","doi-asserted-by":"crossref","first-page":"21662","DOI":"10.1200\/JCO.22.00332","article-title":"Nivolumab plus ipilimumab versus EXTREME regimen as first-line treatment for recurrent\/metastatic squamous cell carcinoma of the head and neck: the final results of CheckMate 651","volume":"41","author":"Haddad","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105840_bib27","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003091","article-title":"Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors","volume":"10","author":"Cristescu","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105840_bib28","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1001\/jamaoncol.2018.4628","article-title":"Safety and efficacy of durvalumab with or without tremelimumab in patients with PD-L1-low\/negative recurrent or metastatic HNSCC: the phase 2 CONDOR randomized clinical trial","volume":"5","author":"Siu","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.esmoop.2025.105840_bib29","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ejca.2018.11.015","article-title":"Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: results from a single-arm, phase II study in patients with >\/=25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy","volume":"107","author":"Zandberg","year":"2019","journal-title":"Eur J Cancer"},{"issue":"10212","key":"10.1016\/j.esmoop.2025.105840_bib30","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"issue":"10167","key":"10.1016\/j.esmoop.2025.105840_bib31","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0140-6736(18)31999-8","article-title":"Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study","volume":"393","author":"Cohen","year":"2019","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.esmoop.2025.105840_bib32","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105840_bib33","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrclinonc.2016.58","article-title":"Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination","volume":"13","author":"Boutros","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105840_bib34","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.oraloncology.2010.08.013","article-title":"Phase II study of vinorelbine\/cetuximab in patients with recurrent\/metastatic squamous cell carcinoma of the head and neck progressing after at least two chemotherapy regimens","volume":"46","author":"Massa","year":"2010","journal-title":"Oral Oncol"},{"issue":"16","key":"10.1016\/j.esmoop.2025.105840_bib35","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1016\/j.cell.2022.06.018","article-title":"Tissue-resident memory and circulating T cells are early responders to pre-surgical cancer immunotherapy","volume":"185","author":"Luoma","year":"2022","journal-title":"Cell"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925017090?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925017090?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T01:51:25Z","timestamp":1773280285000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702925017090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":35,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S2059702925017090"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105840","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MOVIE phase II trial of tremelimumab plus durvalumab combined with metronomic oral vinorelbine in patients with head and neck cancer","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105840","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"105840"}}